Free Trial
CVE:IPA

ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

ImmunoPrecise Antibodies logo
C$6.50
+0.05 (+0.78%)
(As of 11/25/2022)

About ImmunoPrecise Antibodies Stock (CVE:IPA)

Key Stats

Today's Range
C$6.19
C$6.70
50-Day Range
C$6.50
C$6.50
52-Week Range
C$4.52
C$8.81
Volume
19,980 shs
Average Volume
19,376 shs
Market Capitalization
C$162.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

IPA Stock News Headlines

ImmunoPrecise Antibodies to Join AI Drug Summit
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

IPA Stock Analysis - Frequently Asked Questions

ImmunoPrecise Antibodies' stock was trading at C$6.50 at the start of the year. Since then, IPA stock has increased by 0.0% and is now trading at C$6.50.
View the best growth stocks for 2024 here
.

Shares of IPA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include Kraken Robotics (PNG), Facedrive (FDVRF), TrueContext (PFM), UGE International (UGE), Xebec Adsorption Inc. (XBC.V) (XBC.V), Automatic Data Processing (ADP) and Atlas Engineered Products (AEP).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$19.47 million
Cash Flow
C$0.77 per share
Book Value
C$2.67 per share

Miscellaneous

Free Float
N/A
Market Cap
C$162.08 million
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (CVE:IPA) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners